Trial Profile
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Capecitabine; Epirubicin; Exemestane; Fulvestrant; Letrozole; Paclitaxel; Tamoxifen; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PADMA
- 11 Feb 2021 Planned number of patients changed from 260 to 150.
- 01 Feb 2021 Planned End Date changed from 31 Dec 2021 to 31 Mar 2023.
- 01 Feb 2021 Planned primary completion date changed from 31 Dec 2021 to 31 Mar 2023.